Effect of deprenyl on the progression of disability in early Parkinson's disease

The New England Journal of Medicine
Parkinson Study Group

Abstract

In a clinical trial that is still in progress, we studied the ability of deprenyl and tocopherol, antioxidative agents that act through complementary mechanisms, to delay the onset of disability necessitating levodopa therapy (the primary end point) in patients with early, untreated Parkinson's disease. Eight hundred subjects were randomly assigned in a two-by-two factorial design to receive deprenyl, tocopherol, a combination of both drugs, or placebo, and were followed up to determine the frequency of development of the end point. The interim results of independent monitoring prompted a preliminary comparison of the 401 subjects assigned to tocopherol or placebo with the 399 subjects assigned to deprenyl, alone or with tocopherol. Only 97 subjects who received deprenyl reached the end point during an average 12 months of follow-up, as compared with 176 subjects who did not receive deprenyl (P less than 10(-8). The risk of reaching the end point was reduced by 57 percent for the subjects who received deprenyl (Cox hazard ratio, 0.43; 95 percent confidence limits, 0.33 and 0.55; P less than 10(-10]. The subjects who received deprenyl also had a significant reduction in their risk of having to give up full-time employment (P = 0...Continue Reading

References

Dec 1, 1978·British Journal of Clinical Pharmacology·G P ReynoldsG M Stern
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Oct 25, 1986·Lancet·N QuinnC D Marsden
Feb 1, 1988·Clinical Neuropharmacology·L I GolbeR C Duvoisin
Dec 1, 1988·Archives of Neurology·L I GolbeP H Davis
Apr 1, 1987·Neurology·C G GoetzK M Shannon
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Jan 1, 1981·Neurology·T EislerD B Calne
Jan 1, 1983·Modern Problems of Pharmacopsychiatry·W BirkmayerM B Youdim
Jan 1, 1983·Modern Problems of Pharmacopsychiatry·G M SternM Sandler
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·E Csanda, M Tárczy
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·J Knoll
Feb 1, 1984·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·S Fahn, S B Bressman
Feb 1, 1981·Neurology·C H Markham, S G Diamond
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Apr 1, 1984·Archives of Disease in Childhood

❮ Previous
Next ❯

Citations

Oct 14, 2009·Archives of Neurology·Alberto AscherioUNKNOWN Parkinson Study Group DATATOP Investigators
Aug 6, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·G T StebbinsE Cubo
Apr 1, 2003·Annals of Neurology·David J Brooks
Apr 1, 2003·Annals of Neurology·Fabrizio Stocchi, C Warren Olanow
Mar 1, 1990·Annals of Neurology·L I GolbeR C Duvoisin
Sep 1, 1991·Annals of Neurology·S J Boyson
Jan 1, 1992·Annals of Neurology·I Shoulson
Apr 1, 1993·Annals of Neurology·J H KurthJ D Schwankhaus
Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Jan 1, 1994·Journal of Clinical Pharmacology·M J RowlandL B Hendry
Dec 1, 1991·Journal of Neuroscience Research·W G Tatton, C E Greenwood
Feb 1, 1992·Journal of Neuroscience Research·P T Salo, W G Tatton
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·W G JohnsonR Duvoisin
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·M B YoudimP Riederer
Jul 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·G V Sawle
Oct 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·R A Hauser, C W Olanow
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·C W Olanow
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·M B Youdim, P Riederer
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·K T Finnegan
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·W G Tatton
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·J O Rinne
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·H AllainH C Neukirch
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·V V MyllyläE H Heinonen
May 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·G S HotamisligilJ Sullivan
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·C G GoetzC D Marsden
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·S PrzedborskiS Fahn
Jul 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·J LyytinenH Teräväinen
Feb 6, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J H CarterK Zoog
Aug 1, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·G T Stebbins, C G Goetz
Aug 1, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·O RascolA Lees
Feb 7, 2002·Pharmacoepidemiology and Drug Safety·D A van de VijverA de Boer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.